M&A Deal Summary

Aurobindo Pharma Acquires Generis Farmacêutica S.A.

On January 7, 2017, Aurobindo Pharma acquired life science company Generis Farmacêutica S.A. from Magnum Capital Industrial Partners for 135M EUR

Acquisition Highlights
  • This is Aurobindo Pharma’s 3rd transaction in the Life Science sector.
  • This is Aurobindo Pharma’s 0th largest (disclosed) transaction.
  • This is Aurobindo Pharma’s 1st transaction in Portugal.

M&A Deal Summary
Date 2017-01-07
Target Generis Farmacêutica S.A.
Sector Life Science
Buyer(s) Aurobindo Pharma
Sellers(s) Magnum Capital Industrial Partners
Deal Type Add-on Acquisition
Deal Value 135M EUR

Target

Generis Farmacêutica S.A.

Amadora, Portugal
Generis Farmacêutica S.A. is a company engaged in the manufacture and sale of pharmaceutical products in Portugal. Company exports its products directly to hospitals, clinics, pharmacies, and others or through partnerships with local agents and/or distributors in Portugal and internationally.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Aurobindo Pharma

Hyderabad, India
Category Company
Founded 1986
Sector Life Science
Employees19,364
Revenue 287.0B INR (2024)
DESCRIPTION

Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, Japan PMDA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. Aurobindo Pharma was founded in 1986 and is based in Hyderabad, India.

DEAL STATS #
Overall 3 of 4
Sector (Life Science) 3 of 4
Type (Add-on Acquisition) 2 of 3
Country (Portugal) 1 of 2
Year (2017) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2013-09-13 Hyacinths Pharma Pvt.

India

Hyacinths Pharma Pvt. Ltd. is a provider of active pharmaceutical ingredients.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2017-01-09 GENERIS Farmacêutica S.A.

Amadora, Portugal

GENERIS® Farmacêutica, S.A. is a drug development, contract manufacturing and licensing-out company specialized in the manufacturing of solid oral dosage forms.

Buy €135M

Seller(S) 1

SELLER

Magnum Capital Industrial Partners

Madrid, Spain

Investor Investor Investor Investor Investor

Category Private Equity Firm
Founded 2006
PE ASSETS 1.0B EUR
Size Large
Type Sector Agnostic
DESCRIPTION

Magnum Capital is a private equity firm focused on investing in upper middle-market companies located in Spain and Portugal. Magnum prefers control investments in the industrial and service sectors. The Firm's target investment size is €30 to €100 million in businesses valued from €150 to €800 million. Prospective investment situations include family-owned companies with potential for 'increased operating efficiencies', corporate spin-offs, shareholder liquidity needs, and Iberian companies looking to expand beyond the local area. Magnum Capital was formed in 2006 and has offices in Madrid and Lisbon.

DEAL STATS #
Overall 7 of 16
Sector (Life Science) 2 of 2
Type (Add-on Acquisition) 1 of 6
Country (Portugal) 3 of 3
Year (2017) 4 of 6
Size (of disclosed) 4 of 6
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2017-01-07 GENERIS Farmacêutica S.A.

Amadora, Portugal

GENERIS® Farmacêutica, S.A. is a drug development, contract manufacturing and licensing-out company specialized in the manufacturing of solid oral dosage forms.

Sell USD135M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2017-02-22 Globeducate

Madrid, Spain

Globeducate is a provider of technical training and certification programs, conferences, industry standards, reports, publications, technical journals, and government relations activities. Globeducate was founded in 1972 and is based in Madrid, Spain.

Sell -
Mergr

Product

Company

Legal